Back to top

Tale of the Tape

Zacks Equity Research

Why BioScrip (BIOS) Could Be Positioned for a Slump
November 25, 2016

BIOS GALE

Trades from $3

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is BioScrip, Inc. (BIOS - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in BIOS.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 3 estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from loss of 29 cents a share a month ago to its current level of loss of 43 cents per share.

Also, for the current quarter, BioScrip has seen 3 downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to loss of 8 cents a share from loss of 2 cents over the past 30 days.  

BIOSCRIP INC Price and Consensus

The stock also has seen some pretty dismal trading lately, as the share price has dropped 55.7% in the past month.

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical sector, you may instead consider a better-ranked stock Galena Biopharma, Inc. (GALE - Free Report) . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>


In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BIOSCRIP INC (BIOS) - free report >>

GALENA BIOPHARM (GALE) - free report >>